Company: CSTL
Filing Date: 2025-04-09
Form Type: DEF 14A
Source: 0001447362-25-000054
Chunk: 59

Company: CASTLE BIOSCIENCES INC
Filing Date: 2025-04-09
Form: DEF 14A
Chunk 59
---
.2 | %       |
| Tobin W. Juvenal        |     |                                  | 30.8 | %         |     |  55.0 | %      |     |  79.2 | %       |
| Kristen M. Oelschlager  |     |                                  | 30.8 | %         |     |  55.0 | %      |     |  79.2 | %       |

Payouts for the annual performance-based cash bonus are also based on the achievement of individual performance goals, other than for Mr. Maetzold, whose cash bonus award opportunity is based 100% on corporate performance goals. For the other NEOs, 80% of their cash bonus award opportunity is based on the achievement of corporate performance goals, with the remaining 20% based on individual performance goals. The individual performance factor can then be adjusted by a multiplier–up or down–depending upon the Compensation Committee’s assessment. The individual performance multipliers for the other NEOs are the same multipliers used for all other Castle employees. The Compensation Committee assesses the individual performance factor attainment that determines this component (taking into consideration the assessment by the CEO) for the other NEOs. The Compensation Committee then makes a recommendation to the independent members of the board for review and approval. Payments related to the achievement of individual performance goals over the target level are reported as a discretionary bonus, as discussed further below.

The table below reflects the 2024 corporate performance goals for the 2024 annual bonus plan and the resulting achievement approved by the independent members of our Board in January 2025, at the recommendation of the Compensation Committee.

| Goal Category         |     | Corporate Performance Goals                                    |     | Target                                         |     | Actual                                          |     |       | Target Weighting |     |       | Actual Weighting |    |
| Revenue               |     | Revenue for the year ended December 31, 2024                   |     | $305.0 million                                 |     | $332.1 million                                  |     |  75.0 | %                |     | 108.8 | %                | -1 |
| Long term Initiatives |     | •Validation of inflammatory skin disease test                  
 •Achievement of certain electronic ordering metrics            
 •Achievement of certain reimbursement rates for DecisionDx-SCC |     | •Achieve specified validation study            
 •Achieve specified electronic ordering metrics 
 •Achieve specified reimbursement rates         |     | •Spec